Genomic approaches to identifying targets for treating β hemoglobinopathies

Area of Science:

• Genetics
• Hematology
• Genomics

Background:

• Sickle cell disease (SCD) and beta thalassemia are severe genetic blood disorders with limited effective treatments.
• Fetal hemoglobin (HbF) is a key modulator of SCD and beta thalassemia phenotypes, inhibiting deoxyhemoglobin S polymerization and compensating for reduced adult hemoglobin.
• Genomic studies have significantly advanced understanding of HbF genetic regulation.

Purpose of the Study:

• To identify genetic modifiers of fetal hemoglobin (HbF) production.
• To explore therapeutic strategies for increasing HbF levels in patients with SCD and beta thalassemia.

Main Methods:

• Genomic approaches to identify quantitative trait loci (QTLs) for HbF levels.
• Leveraging advances in high-throughput drug screening and genome editing.

Main Results:

• Identification of major QTLs regulating HbF production.
• Potential for therapeutic targets to increase HbF levels.

Conclusions:

• Increasing HbF to therapeutic levels could reverse the pathophysiology of SCD and beta thalassemia.
• New genomic targets, drug screening, and genome editing offer novel therapeutic avenues.